David A. Reardon

Phase I Trial of Temozolomide Plus <i>O</i>⁶-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Purpose We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O 6 -BG e...

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

ClinicalTrials.gov Identifier: NCT02017717.

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain meta...

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important adv...